Rein Therapeutics Inc. (RNTX)

Rein Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	10.9	13.86	11.36	9.68	9.6
Research & Development	11.03	14.25	3.99	17.97	17.01
Other Operating Expenses	28.7	37	0.93	-	-
Total Operating Expenses	50.63	65.11	16.28	27.65	26.61
Operating Income	-50.63	-65.11	-16.28	-27.65	-26.61
Total Non-Operating Income (Expense)	0.05	0.69	0.54	0.32	0.44
Pretax Income	-50.58	-64.43	-15.73	-27.33	-26.16
Provision for Income Taxes	-0.71	-1.54	-	-	-
Net Income	-49.87	-62.88	-15.73	-27.33	-26.16
Net Income to Common	-49.87	-62.88	-15.73	-27.33	-26.16
Shares Outstanding (Basic)	25	18	5	5	4
Shares Outstanding (Diluted)	25	18	5	5	4
Shares Change (YoY)	41.84%	290.09%	1.31%	2.23%	154.71%
EPS (Basic)	-1.96	-3.51	-3.42	-6.02	-5.89
EPS (Diluted)	-1.96	-3.51	-3.42	-6.02	-5.89
Shares Outstanding	27.55	21.67	-	-	-
Free Cash Flow	-19.36	-22.29	-19.81	-24.87	-23.91
Free Cash Flow Per Share	-0.76	-1.24	-4.31	-5.48	-5.38
EBITDA	-50.63	-65.05	-16.16	-27.48	-26.48
EBIT	-50.63	-65.11	-16.28	-27.65	-26.61
Effective Tax Rate	1.41%	2.40%	0.00%	0.00%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q